Modulated electro-hyperthermia applied as monotherapy for various cases having no other options

Taesig Jeung¹, Sun Young Ma¹, Ji Hoon Choi¹, Jae Sang Yu¹, Sangwook Lim¹, Oliver Szasz²

(1) Kosin University Gospel Hospital, Korea
(2) CEO of Oncotherm GmbH, Troisdorf, Germany

Introduction: Cancer has limited curative possibilities in high-line treatments. Our objective study modulated electro-hyperthermia (mEHT) [2], as monotherapy, treating patients in advanced stages, when other possibilities was not applicable.

Methods: This study reports 16 patients, treated by mEHT (EHY2000+ device). 3 pancreas, 3 lung adenocarcinoma, 2 gastric, 2 colorectal and 1-1 synovial, bladder, hepatocellular, ovary, renal and cystic cases. mEHT was applied like chronic treatment numerous times (4-82 sessions) for a long time (months), 2-3 times a week. Sessions were 60 min. each12 sessions in one cycle. The average number of sessions was 33. In most of the cases both the primary and metastatic lesions were treated in independent sessions, or when the metastasis was near than covered both by the large electrode. Control of the cases was made by regular imaging and by the appropriate tumor-markers.

Results: All patients had benefit from the treatments. Although complete remission was not achieved due to the advanced stages, but good partial remission was very common. Despite of the generally short expected survival in these cases, the long mEHT treatment processes were available, well improving the survival time compare to the historical expectations. Definite reducing of pain (improved quality of life) and no remarkable mEHT related side effect was observed, despite the definite dose escalation. In some cases skin erythema appeared, handled with appropriate cream. It did not terminate any further treatments. In some cases ascites made complications of the treatments, but could it be controlled by appropriate medication.